您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > IV-361
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
IV-361
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
IV-361图片
CAS NO:2055741-39-2
包装与价格：
包装价格(元)
5mg电议
10mg电议

产品介绍
IV-361 是一种口服有效，选择性的 CDK7 抑制剂 (Ki≤50 nM)。IV-361 具有抗肿瘤作用 (US20190256531A1)。
Cas No.2055741-39-2
分子式C23H32FN5O2Si
分子量457.62
溶解度DMSO : 90 mg/mL (196.67 mM; Need ultrasonic)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1)[1].

IV-361 has less inhibition on CDK2 (Ki≥1000 nM) or PLK1 (Ki≥5000 nM)[1]. IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC50≤100 nM) in periphery blood mononuclear cell (PBMC)[1]. IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI50≤100 nM)[1].

IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116[1].

[1]. Noriaki Iwase, et al. Substituted dihydropyrrolopyrazole derivative. US20190256531A1.